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ABSTRACT
Objectives: Recurrent vulvovaginitis remains difficult to diagnose accurately and to treat. The
present investigation evaluated the utility of testing vaginal specimens from women with symptom-
atic recurrent vulvovaginitis for Candida species by polymerase chain reaction (PCR) and for
cytokine responses.
Methods: Sixty-one consecutive symptomatic women with pruritus, erythema, and/or a thick
white discharge and a history ofrecurrent vulvovaginitis and 31 asymptomatic women with no such
history were studied. Vaginal swabs were tested for Candida species by PCR, for the antiinflam-
matory cytokine interleukin (IL)-10, and for the proinflammatory cytokine IL-12.
Results: C. albicans was detected in 19 (31.1%) of the patients as well as in three (9.7%) controls
(P 0.03). Both IL-10 (31.1% vs. 0%).and IL-12 (42.6% vs. 6.5%) were also more prevalent in the
recurrent vulvovaginitis patients (P < 0.001). However, there was no relation between the presence
or absence of Candida and either cytokine. Detection of IL-12 in 14 women indicated the stimu-
lation of a vaginal cell-mediated immune response possibly from an infectious agent. The presence
of only IL-10 in six patients indicated a suppression of vaginal cell-mediated immunity and was
consistent with a possible allergic etiology. The absence of both IL-10 and IL-12 in other patients,
similar to that found in healthy controls, suggested a noninfectious, nonallergic etiology of their
symptoms.
Conclusion: Many women with recurrent vulvovaginitis are not infected with Candida. Testing
for Candida should be required in this population. Treatment with only anti-Candida medication
will clearly be inadequate for the majority of women with this condition. Infect. Dis. Obstet. Gy-
necol. 8:244-247, 2000. (C) 2000 Wiley-Liss, Inc.
KEY WORDS
recurrent vulvovaginitis; interleukin-12; interleukin-10; Candida
ecurrent vulvovaginitis remains a difficult dis-
order to diagnose accurately, to treat, and for
which to end the repetitive cycles. There is a wide-
spread assumption that a Candida infection is al-
ways, or nearly always, involved in eliciting the
associated symptoms. The sale of nonprescription
drugs for self-treatment of vaginal "yeast" infec-
tions is many times greater than the number of
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infected women. Many clinicans also treat on the
basis of clinical symptoms, without confirmation
that Candida is indeed present. This may account,
in part, for the ineffectiveness of antifungal treat-
ments in many women.
There is an increasing awareness that a localized
immune perturbation may lead to vulvovaginitis in
some women. A localized allergic response in the
vagina has been demonstrated. 1-4 Vaginal symp-
toms may be due to an immediate hypersensitivity
response to infectious agents or to noninfectious
allergens
1-3 as well as to eosinophil accumulation.4
The subsequent production of prostaglandin E z
and inhibition of cell-mediated immune re-
sponses 1,s would also favor proliferation of Candida
or other microorganisms to levels capable of elicit-
ing clinical symptoms.
To obtain a more accurate diagnosis of women
with recurrent vulvovaginitis as the basis for selec-
tive treatment, we analyzed vaginal specimens
from women with this disorder for Candida .species
by polymerase chain reaction (PCR) and for vaginal
concentrations of interleukin (IL)-12 and IL-10.
Induction of specific immune responses is largely
dependent on IL-12. Only those T lymphocytes
belonging to the Thl subset express the 13 chain of
the IL-12 receptor. Binding of IL-12 to this recep-
tor leads to Thl lymphocyte activation and induc-
tion of a cell-mediated immune response.
6 This is
the mechanism responsible for limiting Candida
growth in the vagina. However, in the absence of
IL-12 [3-receptor expression, the T lymphocytes
develop along the Th2 pathway. This leads to IL-
l0 release, production of IgE, induction of an al-
lergic response, and inhibition of cell-mediated im-
munity. 7 Under these conditions, vaginal Candida
yeast can multiply and begin to germinate into
their hyphal form.8
MATERIALS AND METHODS
Subjects
The study population consisted of 61 consecu-
tive women with at least four previous episodes of
symptomatic vulvovaginitis in the past 12 months
and who were currently complaining of pruritis, er-
ythema, and/or a vaginal discharge. Thirty-one con-
secutive asymptomatic women seen at the same
center with no self-reported history of vulvovagini-
tis and no evidence of a current vaginal infection or
inflammation were also studied. All subjects were
white. Women with herpesvirus, human papilloma-
virus, and bacterial vaginosis as defined by clinical
criteria were excluded. All subjects were tested for
Mycoplasma hominis, Ureaplasma urealyticum, Chla-
mydia trachomatis, Neisseria gonorrhoeae, syphilis,
and HIV. None was receiving medication at the
time of the study and for at least 4 weeks previ-
ously. Informed consent was obtained from each
participant.
Specimen Collection
A vaginal specimen was obtained by instilling
1.0 ml phosphate-buffered saline (PBS) into the
posterior vagina, rubbing the lateral walls with a
cotton swab, and removing the specimen with a
syringe. The sample was centrifuged, and the su-
pernatant and pellet were frozen separately at
-80C until tested.
Candida Testing
The pellet fractions were thawed, treated with
lyticase to disrupt the Candida cell wall, and tested
for C. albicans by PCR.9 This assay has previously
been demonstrated to detect all C. albicans culture-
positive specimens from the vagina as well as in
additional culture-negative specimens.,11 Nega-
tive specimens were retested by another PCR that
is able to detect all other Candida species.z
Cytokine Analysis
The supernatant fractions were thawed and as-
sayed for IL-10 and IL-12 by commercial ELISA
assays (BioSource, Camarillo, CA). Values were
converted to picograms per milliliter by reference
to a standard curve generated in parallel to the test
specimens. The lower limits of sensitivity were 5
pg/ml for IL-10 and pg/ml for IL- 12. The positive
values ranged from 10 to 144 pg/ml for IL-10 and
from 31 to 164 pg/ml for IL-12. Duplicate values
differing by more than 10% were reassayed.
Statistical Analysis
Differences between variables were evaluated
by Fisher’s exact test and the nonparametric
Mann-Whitney test, as appropriate. A P value
<0.05 was considered significant.
RESULTS
Demographic and Historical Variables
A comparison of the patient and control popula-
tions is shown in Table 1. There were no statisti-
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TABLE I. Demographic and historical variables in
patients and controls
Variable
Patients Controls
(n 61) (n 31)
Mean age (S.D.)in years 31.6 (7.1) 34.4 (6.2)
Mean no. pregnancies (S.D.) I. (I.2) I. (I.0)
Allergic history (%) 43.7 32.3
Current smoker (%) 16.3 25.8
Oral contraceptive user (%) 26.3 35.4
"Self-reported history of seasonal or food allergies or allergic responses
to medications.
cally significant differences in any of the variables
examined. Except for detection of M. hominis and/
or U. urealyticum in seven of the patients, none of
the patients or controls was currently positive for
any of the non-Candida microorganisms examined.
The presence of these mycoplasmas appeared to
be unrelated to the cytokine findings.
Detection of Vaginal Candida Species and
Vaginal Cytokines
C. a/bicans was detected in the vaginal speci-
mens from only 19 (31.1%) of the women with
symptomatic recurrent vulvovaginitis. Three
(9.7%) of the healthy controls were also positive for
this organism (P 0.03). No additional Candida
species were detected in any of the specimens.
IL-12 was present in 42.6% of the vaginal
samples from symptomatic women with recurrent
vulvovaginitis, and 31.1% were positive for IL-10.
In contrast, only two (6.5%) control vaginal speci-
men contained IL-12, and none was positive for
IL-10 (P < 0.001). There was no relation between
the presence or absence of Candida in the recurrent
vulvovaginitis patients and any of the variables ex-
amined (Table 2).
The relationships between cytokine and Can-
dida detection in the recurrent vulvovaginitis pa-
tients are detailed in Table 3. In almost one-third
of the symptomatic patients, neither Candida nor
IL-12 or IL-10 was detected. A mixture of IL-12
and IL-10 was present in 14 women, 12 had only
IL-12, and 6 were positive only for IL-10 in their
vaginas. In nine women, Candida was detected in
the absence of eithercytokine.
DISCUSSION
By utilizing the very sensitive PCR, C a/hi-
cans was identified in only 31.1% of symptomatic
TABLE 2. Relation between C. albicans and various
parameters in women with symptomatic recurrent
vulvovaginitis
Variable
Candida Candida
present absent
(n 19) (n 42)
Vaginal interleukin-12 (%) 47.4 38.6
Vaginal interleukin-10 (%) 31.6 31.8
Allergic history (%) 31.6 36.4
Current smoker (%) 10.5 9.
Mean No. pregnancies (S.D.) 1.4 (I.2) I. (I.3)
Mean age (S.D.)in years 33.2 (7.2) 31.0 (7.4)
Mean no. episodes of vaginitis per
year (S.D.) 8.7 (2.5) 8.2 (7.4)
Oral contraceptive user (%) 31.5 55.8
TABLE 3. Detection of IL-10, IL-12, and C. albicans
in vaginal specimens from women during an episode
of recurrent vulvovaginitis
Cytokines Candida No. patients (%)
Only IL-10 Present (I.6)
Only IL-10 Absent 5 (8.2)
Only IL-12 Present 4 (6.6)
Only IL-12 Absent 8 (I 3. I)
IL-12, IL-10 Present 5 (8.2)
IL-12, IL-10 Absent 9 (14.8)
None Present 9 (14.8)
None Absent 20 (32.8)
women with recurrent vulvovaginitis; none was
positive for other Candida species. Therefore, the
vaginal symptoms in the majority of these patients
were not due to the presence of Candida at this
anatomical site. In addition, there was no consis-
tent pattern of vaginal cytokine production in these
women.
The heterogeneity of cytokine responses indi-
cates multiple etiologies of the clinical symptoms.
The presence of IL-12 in 26 of the patients indi-
cated a localized cell-mediated immune activation,
consistent with a possible infectious etiology for
their symptoms. The finding of IL-10 in some of
the IL-12-positive samples probably indicates acti-
vation of the immune regulatory mechanism nec-
essary to limit the extent of the proinflammatory
response. IL-12 has been shown to induce IL-10
production. 13 Candida proliferation might have
stimulated production of IL-12 and IL-10 in the
women positive for this organism, but this was
clearly not the case for the majority of patients
examined. Although women with bacterial vagino-
sis were excluded from this study, quantitative mi-
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crobial cultures for aerobic and anaerobic microor-
ganisms were not available for the present subjects,
so the possible role of other microbes in eliciting
the vaginal symptoms remains undetermined.
The absence of vaginal IL-12 in 10 of 19 sub-
jects who were positive for C. albicans strongly sug-
gests a deficiency in the ability to mount a vaginal
cell-mediated immune reaction in response to this
microorganism. This lack of an appropriate im-
mune response may contribute to susceptibility to
recurrent vaginal candidiasis in these women. Simi-
larly, detection of IL-10 in the absence of IL- 12 in
six women is consistent with induction of an aller-
gic Th2-mediated immune response being in-
volved in the symptomatology of vulvovaginitis.
The absence of IL-10, IL-12, and Candida in
32.8% of the symptomatic patients indicates the
probable absence of an infectious or allergic etiol-
ogy in these women. The cause(s) of their vaginal
symptoms remains unknown and is currently under
investigation. More detailed microbiological, im-
munological, and genetic testing may be necessary
to resolve this question.
The absence of Candida species in most of the
study subjects with symptomatic recurrent vulvogi-
nitis points out that treatment with an antiyeast
medication will be both ineffective and inappropri-
ate for many women with recurrent vulvovaginitis.
Clearly, there are multiple etiologies contributing
to similar symptoms in women with vulvovaginitis
and this problem is not as simple to diagnose ac-
curately as many clinicians and lay people believe.
An improved capacity to make individualized diag-
noses, perhaps by incorporating testing for IL-12,
IL-10, and/or other cytokines or mediators indica-
tive of infection, allergy, or other immune pro-
cesses, and subsequent appropriate treatment, may
improve our capabilities to treat more effectively
vulvovaginitis in these women. Further studies are
needed to validate cytokine analyses for determin-
ing the etiology of vulvovaginal symptoms.
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